Literature DB >> 26465194

Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.

Logan K Wink1, Ernest V Pedapati1, Paul S Horn1, Christopher J McDougle2, Craig A Erickson1.   

Abstract

OBJECTIVE: The purpose of this study was to explore the use of multiple antipsychotic medications in patients with autism spectrum disorder (ASD) by reviewing the longitudinal medication management of 1100 patients consecutively treated for behavioral symptoms associated with ASD at a tertiary care specialty clinic.
METHODS: We identified all patients with ASD treated with daily doses of two or more antipsychotics for at least two visits at our clinic. For each patient meeting inclusion criteria, diagnostic and demographic data were collected. To evaluate clinical need and effectiveness of antipsychotic medications in this sample, we reviewed symptoms targeted with each antipsychotic medication and concomitant medications prescribed. Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scale ratings had been completed at the time of each visit, and the duration of treatment with antipsychotic medications was determined. To evaluate the safety and tolerability of antipsychotic medication use in ASD, we reviewed reported adverse effects and calculated body mass index (BMI) change with treatment.
RESULTS: Seventy patients met the inclusion criteria (6.4% of our sample). The majority of patients were moderately to severely ill Caucasian males, as determined by baseline mean CGI-S of 4.7 (SD = 0.8), and were diagnosed with autistic disorder and comorbid intellectual disability. The mean age was 15.1 years (SD = 10.9), the primary targeted symptoms were agitation/irritability, physical aggression, and self-injury. The majority of patients remained on two or more antipsychotics for >1 year. In this population, patients demonstrated greater symptomatic improvement and generally tolerated treatment without significant adverse effects.
CONCLUSIONS: The use of two or more antipsychotic medications may be increasingly common in patients with ASD. This retrospective study demonstrates that this treatment approach may be of some clinical benefit, and is generally well tolerated. Prospective studies focusing on the efficacy and safety of concomitant antipsychotic medication usage in ASD should be considered.

Entities:  

Keywords:  antipsychotics; autism; autism spectrum disorder; irritability; physcopharmacology

Mesh:

Substances:

Year:  2015        PMID: 26465194      PMCID: PMC5335810          DOI: 10.1089/cap.2015.0123

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  13 in total

1.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

2.  Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.

Authors:  Logan K Wink; Maureen Early; Tori Schaefer; Amy Pottenger; Paul Horn; Christopher J McDougle; Craig A Erickson
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-02-24       Impact factor: 2.576

3.  Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program.

Authors:  Robert J Constantine; Timothy Boaz; Rajiv Tandon
Journal:  Clin Ther       Date:  2010-05       Impact factor: 3.393

4.  Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.

Authors:  Benjamin A Adler; Logan K Wink; Maureen Early; Rebecca Shaffer; Noha Minshawi; Christopher J McDougle; Craig A Erickson
Journal:  Autism       Date:  2014-02-26

5.  Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Authors:  Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn
Journal:  Pharmacotherapy       Date:  2014-07-03       Impact factor: 4.705

Review 6.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

Review 7.  Psychopharmacologic management of serious behavioral disturbance in ASD.

Authors:  Kimberly A Stigler
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-09-14

Review 8.  Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.

Authors:  Laura C Politte; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2013-04-04       Impact factor: 4.530

9.  Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program.

Authors:  Jane R Schubart; Fabian Camacho; Douglas Leslie
Journal:  Autism       Date:  2013-10-28

10.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.

Authors:  Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

View more
  6 in total

1.  Predicting aggression to others in youth with autism using a wearable biosensor.

Authors:  Matthew S Goodwin; Carla A Mazefsky; Stratis Ioannidis; Deniz Erdogmus; Matthew Siegel
Journal:  Autism Res       Date:  2019-06-21       Impact factor: 5.216

2.  Predicting Imminent Aggression Onset in Minimally-Verbal Youth with Autism Spectrum Disorder Using Preceding Physiological Signals.

Authors:  Matthew S Goodwin; Ozan Özdenizci; Catalina Cumpanasoiu; Peng Tian; Yuan Guo; Amy Stedman; Christine Peura; Carla Mazefsky; Matthew Siegel; Deniz Erdoğmuş; Stratis Ioannidis
Journal:  Int Conf Pervasive Comput Technol Healthc       Date:  2018-05

3.  A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder.

Authors:  Logan K Wink; Ryan Adams; Paul S Horn; Charles R Tessier; Andrew P Bantel; Michael Hong; Rebecca C Shaffer; Ernest V Pedapati; Craig A Erickson
Journal:  J Autism Dev Disord       Date:  2018-09

4.  Comparison of behaviors characteristic of autism spectrum disorder behaviors and behavioral and psychiatric symptoms of dementia.

Authors:  Elizabeth K Rhodus; Justin Barber; Erin L Abner; Shoshana H Bardach; Allison Gibson; Gregory A Jicha
Journal:  Aging Ment Health       Date:  2020-11-23       Impact factor: 3.658

Review 5.  Aggression in autism spectrum disorder: presentation and treatment options.

Authors:  Sarah E Fitzpatrick; Laura Srivorakiat; Logan K Wink; Ernest V Pedapati; Craig A Erickson
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-23       Impact factor: 2.570

6.  Pharmacogenomic testing: aiding in the management of psychotropic therapy for adolescents with autism spectrum disorders.

Authors:  Seuli Bose-Brill; Jinming Xing; Debra J Barnette; Christopher Hanks
Journal:  Pharmgenomics Pers Med       Date:  2017-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.